This internet posting serves as notice under 35 U.S.C. §287(a) that the following Insulet products may be covered by the following U.S. patent(s). Each product may also be covered by one or more foreign patents, and additional patent application(s) may be pending.

Omnipod® Insulin Management System

11,324,889 (OMNIPOD® 5 Automated Insulin Delivery System)
11,090,434 (OMNIPOD® 5 Automated Insulin Delivery System)
11,229,741 (Omnipod System and Omnipod DASH System)
10,569,011 (Omnipod System and Omnipod DASH System)
10,438,698 (Omnipod DASH® System)
10,420,883 (Omnipod System and Omnipod DASH System)
10,130,758 (Omnipod System and Omnipod DASH System)
9,402,950 (Omnipod System and Omnipod DASH System)
7,771,412 (Omnipod System and Omnipod DASH System)
D874,471 (Omnipod DASH System)
D872,734 (Omnipod DASH System)
D872,733 (Omnipod DASH System)
D869,495 (Omnipod DASH System)
D869,479 (Omnipod DASH System)
D862,500 (Omnipod DASH System)
D851,658 (Omnipod DASH System)
D839,284 (Omnipod DASH System)
D838,731 (Omnipod DASH System)
D836,123 (Omnipod DASH System)
D826,957 (Omnipod DASH System)
D826,956 (Omnipod DASH System)

Omnipod® Delivery Systems



Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet's Omnipod® Insulin Management System to bring simplicity and freedom to their lives.